Page last updated: 2024-08-16

temozolomide and azd 6244

temozolomide has been researched along with azd 6244 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Bastholt, L; Cantarini, M; Dummer, R; Hersey, P; Kemsley, K; Kirkwood, JM; Larkin, J; Middleton, M; Robert, C; Sosman, J; Zazulina, V1
Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; LogiƩ, A; Odedra, R; Smith, PD; Wilkinson, RW1
Abramson, DH; Albertini, MR; Ambrosini, G; Ancell, K; Bluth, M; Carvajal, RD; Chapman, PB; Dickson, MA; Doyle, A; Erinjeri, J; Flynn, PJ; Gajewski, TF; Hedvat, C; Joshua, AM; Kudchadkar, RR; Lao, CD; Lawson, DH; Lewis, K; Linette, GP; Lutzky, J; Marr, B; Milhem, MM; Panageas, KS; Quevedo, JF; Sato, T; Schwartz, GK; Sosman, JA; Wolchok, JD1

Trials

2 trial(s) available for temozolomide and azd 6244

ArticleYear
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Disease-Free Survival; DNA Mutational Analysis; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Temozolomide; Treatment Outcome; Young Adult

2012
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
    JAMA, 2014, Jun-18, Volume: 311, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Temozolomide; Treatment Outcome; Uveal Neoplasms

2014

Other Studies

3 other study(ies) available for temozolomide and azd 6244

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    British journal of cancer, 2012, Feb-28, Volume: 106, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Docetaxel; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Taxoids; Temozolomide; Xenograft Model Antitumor Assays

2012
Selumetinib shows promise in metastatic uveal melanoma.
    Cancer discovery, 2013, Volume: 3, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; Dacarbazine; Disease-Free Survival; Eye Neoplasms; Humans; Melanoma; Neoplasm Metastasis; Temozolomide; Uveal Neoplasms

2013